Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials

Magseed Pro(R)/ Sentimag(R) Gen3

NCT05142787
Recruiting
Conditions Breast Cancer
Phase NA
Enrollment 224
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics — placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions

Primary Outcomes

  • The primary endpoints are the retrieval rates of the Magseed Pro® marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions (time of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-02
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 224 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Endomagnetics Ltd.
Principal Investigators:
  • Stefan Paepke, Dr (PRINCIPAL_INVESTIGATOR) - The technical university of Munich
Contact Information
Study Contact:
Matt Womack, Dr
+447851247439
mwomack@endomag.com
Tanja Odeneg, Dr
+441223652604
todeneg@endomag.com
Hans Christian Kolberg
Marienhospital Bottrop GmbH
Interventions
  • Device: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics — placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
Study Locations (6 sites)
Marienhospital Bottrop GmbH, Bottrop, Germany
AGAPLESION Markus Frankfurter Diakonie Kliniken gGmbH, Frankfurt, Germany
Technical University Munich, Munich, Germany
Guy's Hospital, London, United Kingdom
Royal Marsden Hospital, London, United Kingdom
University Hospital South Manchester, Manchester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Participant is aged 18 years or older at the time of consent. * Patients requiring breast lesion/axillary node marking and excision Exclusion Criteria:• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment. * Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results * Known hypersensitivity to Nitinol * Subject has current active infection at the implantation site in the breast (per investigator discretion)
Conditions Breast Cancer
Phase Not Applicable
Enrollment 10000
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Due to better treatment options and earlier detection, survival rates of patients with breast cancer continue to increase. As such, (late) treatment toxicity, (long-term) quality of life and the cosmetic outcome are becoming more important. Also, many competing experimental interventions (e.g. treatment, lifestyle interventions) for breast cancer are being developed, all in need to be properly evaluated before being implemented in routine clinical care. Randomized Controlled Trials are the gold standard to do so, but they have shown many challenges, especially when applied in a cancer setting. The 'cohort multiple Randomized Controlled Trial (cmRCT)' design is a promising design for multiple (simultaneous) randomized evaluations of experimental interventions, with potential for increased recruitment, comparability and long-term outcomes as a standard. By setting up UMBRELLA, as a prospective cohort according to the cmRCT design, the investigators aim to: * provide an infrastructure for efficient, fast and pragmatic evaluation and implementation of experimental interventions * gain insight into short and long-term treatment response, toxicity, complications, quality of life and survival of patients with breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change from baseline Quality of Life at 10 years (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-10
Completion: 2053-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UMC Utrecht
Principal Investigators:
  • Helena M Verkooijen, MD, PhD (PRINCIPAL_INVESTIGATOR) - UMC Utrecht
Contact Information
Study Contact:
Helena M Verkooijen, MD, PhD
h.m.verkooijen@umcutrecht.nl
Danny A Young-Afat, MD
d.a.youngafat@umcutrecht.nl
Danny Evers, MD PhD
Ziekenhuisgroep Twente
Interventions
N/A
Study Locations (4 sites)
Ziekenhuisgroep Twente, Almelo, Netherlands
Alrijne Ziekenhuis, Leiderdorp, Netherlands
St. Antonius Ziekenhuis, Nieuwegein, Netherlands
University Medical Center Utrecht, Utrecht, 3508GA Netherlands
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients with breast cancer who undergo irradiation in the UMC Utrecht * Informed consent - at least - for use of routinely collected clinical data and to fill out questionnaires. Exclusion Criteria: * Inability to understand the Dutch language
Conditions Breast Cancer, Radiation
Phase NA
Enrollment 540
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to validate whether clinically low-risk, and RecurIndex high-risk N1 patients receiving regional lymph node radiotherapy can further improve clinical outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: regional nodal irradiation — external-beam radiotherapy (XRT)
  • Radiation: WBI — Whole Breast Irradiation
  • Radiation: chestwall XRT — chestwall irradiation

Primary Outcomes

  • Invasive disease-free survival (IDFS) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-08-20
Completion: 2030-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Sun Yat-sen University
Contact Information
Study Contact:
Xiaobo Huang, MD
8613556080080
huangxb@mail.sysu.edu.cn
Tan Yuting
8615913198466
tanyt3@mail.sysu.edu.cn
Xiaobo Y Huang, MD
8613556080080
huangxb@mail.sysu.edu.cn
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Interventions
  • Radiation: regional nodal irradiation — external-beam radiotherapy (XRT)
  • Radiation: WBI — Whole Breast Irradiation
  • Radiation: chestwall XRT — chestwall irradiation
Study Locations (1 sites)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old, ≤ 70 years old. * Eastern Cooperative Oncology Group (ECOG) ≤ 2. * Postoperative pathology is clearly diagnosed as invasive breast cancer. * Meet the clinical definition of low risk: ①Axillary lymph node micrometastasis (N1mic) or ②N1 patients who meet the following conditions at the same time, a)Age ≥ 40 years old, b)Vascular tumor thrombus (LVI) negative or allow few positive LVI (excluding extensive or massive LVI), c)Three subtypes are allowed (Lumina A, Lumina B/HER2 negative, Lumina B/HER2 positive) , namely ER positive (ER ≥ 1%), HER2 negative (HER2 expression negative or + by IHC, or 2+ but negative by FISH) or ER positive (ER ≥ 1%), HER2 positive (3+ by IHC, or 2+ but positive by FISH). * Postoperative pathological diagnosis of axillary lymph node status is any of the following: a. Sentinel lymph node biopsy or axillary lymph node dissection for micrometastasis (N1mic), b. Sentinel lymph node biopsy for 1-2 lymph node macrometastasis (N1sln), c. Sentinel lymph node biopsy + axillary lymph node dissection or simple axillary lymph node dissection for 1-3 lymph node metastasis (N1). * The primary tumor and breast undergo breast-conserving surgery or total resection ± breast reconstruction (autologous/prosthetic). * There must be adequate systemic examination (such as chest X-ray, B-ultrasound, CT, etc.) within 3 months before randomization of radiotherapy to confirm that there is no distant metastasis. * No contralateral breast cancer must be confirmed by molybdenum target and/or MRI within 12 months before randomization of radiotherapy. * At least 4 courses of adjuvant chemotherapy with anthracycline or taxane should be completed after surgery. If patients with HR positive, HER2 negative tumor underwent Multigene Assays, with low risk scores, omitting chemotherapy is permitted. * Radiotherapy must be performed sequentially after the completion of adjuvant chemotherapy, starting no later than 8 weeks after the end of chemotherapy. * The patient must have sufficient primary fresh frozen specimens or post-paraffin tissue sections for RecurIndex testing. * No previous history of malignant tumors, except for basal cell carcinoma of the skin. * Signed an informed consent form. Exclusion Criteria: * Postoperative radiotherapy was confirmed as T3-4, N0, N2-3, M1 lesion staging before enrollment. * Receive any new adjuvant therapy before surgery, including chemotherapy, endocrine therapy, targeted therapy or radiation therapy. * Patients who underwent total mastectomy and only sentinel lymph node biopsy. * Have a history of contralateral breast cancer. * History of chest radiotherapy. * combined with severe heart, lung, liver, kidney, hematopoietic, neurological diseases, and mental illness. * History of autoimmune diseases such as scleroderma or active lupus erythematosus. * pregnant and lactating patients.
Conditions Breast Cancer
Phase PHASE2
Enrollment 118
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

* This study was an open, multicenter phase II clinical trial that enrolled 118 patients with HR+/HER2- with recurrent or progressive advanced breast cancer treated with CDK4/6 inhibitors; * The study adopted the Simon phase 2 design, and all 20 eligible patients were treated with entinostat + fulvestrant; The study was terminated if no more than 2 patients achieved objective response and continued to enter Phase 2 if no more than 3 patients achieved objective response. In Phase 2, qualified patients were randomly assigned at a ratio of 1:1.5 to either the entestasta + fluvestrus group (Group 1) or the anlotinib + entestasta + fluvestrus group (Group 2), with 39 patients enrolled in group 1 and 59 patients enrolled in group 2; All patients were treated until the subjects' treatment would continue until the subjects experienced disease progression, intolerable toxicity, active withdrawal from treatment, or other conditions specified in the protocol, whichever occurred first. * During the study period, efficacy evaluations will be conducted every 8 weeks in accordance with the Solid Tumor Efficacy Evaluation Criteria (RECIST) v1.1 until disease progression, the initiation of a new anti-tumor treatment by the subject, or the withdrawal of informed consent, whichever occurs first. * Continuous safety evaluations will be conducted during the study treatment period. All subjects who have received at least one study treatment will be required to undergo end-of-treatment visits and safety follow-up visits within 7 days and 30±2 days after the last study treatment, respectively. * The end of the study was defined as the occurrence of disease progression or the end of the study treatment in all subjects, or the early termination of the study for other reasons, whichever occurred first.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: entinostat — Entinostat tablets, orally once a week (5 mg); Each treatment cycle lasts for 28 days. Treatment will continue until the subject experiences disease progression, intolerable toxicity, voluntary withdrawal, or any other condition specified in the protocol, whichever occurs first.
  • Drug: Fulvestrant — Fulvestrant, intramuscular injection, 500 mg each time, administered on d1 and d15 of the first cycle, and on d1 of each subsequent cycle. Each treatment cycle lasts for 28 days. Treatment will continue until the subject experiences disease progression, intolerable toxicity, voluntary withdrawal, or any other condition specified in the protocol, whichever occurs first.
  • Drug: Anlotinib — Anlotinib, 10mg each time, once daily, orally before breakfast. Take the drug for 2 consecutive weeks and then stop for 1 week, that is, 3 weeks (21 days) as one course of treatment.

Primary Outcomes

  • ORR (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-24
Completion: 2028-11-26
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Cancer Hospital
Contact Information
Study Contact:
Rong Wang
18867509858
jiangsuwangrong2006@126.com
Rong Wang
18867509858
jiangsuwangrong2006@126.com
Zhejiang Cancer Hospital
Interventions
  • Drug: entinostat — Entinostat tablets, orally once a week (5 mg); Each treatment cycle lasts for 28 days. Treatment will continue until the subject experiences disease progression, intolerable toxicity, voluntary withdrawal, or any other condition specified in the protocol, whichever occurs first.
  • Drug: Fulvestrant — Fulvestrant, intramuscular injection, 500 mg each time, administered on d1 and d15 of the first cycle, and on d1 of each subsequent cycle. Each treatment cycle lasts for 28 days. Treatment will continue until the subject experiences disease progression, intolerable toxicity, voluntary withdrawal, or any other condition specified in the protocol, whichever occurs first.
  • Drug: Anlotinib — Anlotinib, 10mg each time, once daily, orally before breakfast. Take the drug for 2 consecutive weeks and then stop for 1 week, that is, 3 weeks (21 days) as one course of treatment.
Study Locations (1 sites)
Zhejiang Cancer Hospital, Zhejiang, Hangzhou 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Sign an informed consent form; 2. Female, aged 18 or above; 3. The patient's Eastern Tumor Collaboration Group (ECOG) physical status is 0-1; 4. The patient's expected survival time is ≥3 months; 5. Breast cancer patients diagnosed as HR-positive and HER-2 negative by tumor histopathological and molecular pathological typing (based on the most recent report); 1) Hormone receptor positive refers to estrogen receptor (ER) positive, progesterone receptor (PR) negative or positive (≥1% positive staining cells are considered receptor positive); 2) HER-2 negative means: the immunohistochemical result of the pathological specimen test is 0 or 1+; Or an immunohistochemical result of 2+ and a negative ISH or FISH test. 6. The subject has received at least one line of endocrine therapy as well as CDK 4/6 inhibitor therapy at an unresectable stage of locally advanced recurrence or metastasis; Or disease recurrence occurred during ET combined with CDK4/6 inhibitors as adjuvant therapy or within 12 months after the end of treatment. 7. The subject has not received chemotherapy or ADC therapy for metastatic disease 8. At least one measurable target lesion was evaluated by the investigator in accordance with RECIST 1.1 9. No known active brain metastases or leptomeningeal disease 10. The patient must have adequate organ function within 1 week (7 days) prior to the initiation of study administration, as defined below: * Hematology: Hemoglobin (HgB) ≥80 g/L, platelet count ≥100×109 /L, absolute neutrophil count ≥1.0×10 /L. Note: Platelet transfusion is not allowed within 3 days before these laboratory tests, red blood cell transfusion is not allowed within 14 days, and hematopoietic growth factor (pegylated G-CSF, 14 days for erythropoietin) is not allowed within 7 days. No blood transfusion or use of auxiliary white blood cell, platelet increase drugs such as cytokines or erythropoietin drugs within 2 weeks prior to the screening test * Renal function: Serum creatinine (Cre) ≤1.5× upper limit of normal (ULN), or glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2. Urine protein \<2+ or 24-hour urine protein quantification \<1g * Liver function: Total bilirubin ≤1.5×ULN; If Gilbert syndrome is present, total bilirubin ≤3 mg/dL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN; If there is liver metastasis, both ALT and AST should be ≤5×ULN; Alkaline phosphatase (ALP) ≤2.5×ULN; If there is bone metastasis, it should be ≤5×ULN. 9\. Echocardiography shows left ejection fraction (LVEF) ≥50% and QTc interval ≤480 ms. 10\. Female patients in the premenopausal or perimenopausal period who agree to use the concomitant luteinizing hormone-releasing hormone (LHRH) agonist can be enrolled. Those who meet any of the following criteria may be considered to have reached menopause, but those who do not meet the criteria for being considered premenopausal or perimenopausal: * Having undergone bilateral oophorectomy in the past; * Age ≥60 years; * Age \<60 years old, natural menopause ≥12 months, no chemotherapy, tamoxifen, torremifen or ovarian function castration during this period, blood follicle-stimulating hormone (FSH) and estradiol (E2) levels within postmenopausal range (judged in combination with the reference range of the research center); 11. Patients who are fertile must agree to use recognized effective methods of contraception (including condoms with inactivated sperm, vaginal separators, oral or injectable contraceptives, etc.) or abstain from sexual activity during their participation in the study and for 3 months after the cessation of study treatment. Exclusion Criteria: * Patients should not be enrolled if any of the following conditions occur: 1. Symptomatic visceral metastases or other conditions, visceral crisis, or the investigator deems it inappropriate to use endocrine therapy; 2. The patient has a past or present central nervous system metastases, or leptomeningeal disease, brain metastases; 3. Previous use of selective estrogen receptor degraders (SERD, such as fulvestrant) or histone deacetylase (HDAC) inhibitors (such as entectamine, chidamide, etc.) or small molecule multi-target tyrosine kinase inhibitors (such as apatinib, anlotinib, etc.) or PAM pathway inhibitors (such as PI3K inhibitor Alpelisib, AKT inhibitor Capivasertib, MTOR inhibitor everolimus, etc. 4. Known allergy to SERD, entinostat, or other drugs with a benzamide structure (such as typapride, remopilib, cloprapride, etc.), anlotinib; 5. Pregnant or lactating women; 6. Coexisting with other malignant tumors, unless radical treatment has been administered and there is no evidence of recurrence or metastasis; 7. There is pericardial effusion requiring drainage, pleural effusion with obvious clinical symptoms or ascites; 8. Other circumstances that the investigator deems unsuitable for inclusion.
Conditions Triple-negative Breast Cancer
Phase PHASE2
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized, open-label clinical study. 128 patients with relapsed or metastatic triple-negative breast cancer (TNBC) who had not been systematically treated are going to be enrolled and randomly assigned to 3 groups. Group A: albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks). Group B: albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks)+ apatinib mesylate tablet (500 mg, orally, once daily, every 3 weeks). Group C: albumin-bound paclitaxel (260mg/m2, intravenous infusion, once every 3 weeks) + bevacizumab (7.5mg/kg, intravenous infusion, once every 3 weeks). The dosages of therapeutic drugs are allowed to be adjusted appropriately according to the toxic reaction of the patients. Patients in three groups continued to take medication until disease progression/death/toxicity was intolerable/the patient or investigator decided to discontinue the medication. The primary endpoint is progression-free survival (PFS). Secondary endpoints are objective response rate (ORR), clinical benefit rate (CBR, complete response (CR)+ partial response (PR) + stable disease (SD, \> 6 months)), overall survival (OS), adverse events (AE), and potential predictive biomarker parameters related to treatment response (VEGF-A expression level) in peripheral blood.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Albumin-Bound Paclitaxel — Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
  • Drug: Apatinib Mesylate — Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
  • Drug: Bevacizumab — Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.

Primary Outcomes

  • Progression-free Survival (PFS) (2 Years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-01-14
Completion: 2027-12-01
Eligibility
Age: 18 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Bengbu Medical University
Principal Investigators:
  • Yan Yang, M.D.,Ph.D (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital of Bengbu Medical University
Contact Information
Study Contact:
Jing Liu, M.D.
+86-0552-3086178
15805692769@163.com
Jing Jing, M.D.
+86-552-3086178
15805692769@163.com
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Yan Yang, M.D., Ph.D.
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College
Interventions
  • Drug: Albumin-Bound Paclitaxel — Albumin-bound paclitaxel is one of the standard first-line regimens for relapsed or metastatic triple-negative breast cancer.
  • Drug: Apatinib Mesylate — Apatinib mesylate is an orally administered small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
  • Drug: Bevacizumab — Bevacizumab is a humanized anti-VEGF monoclonal antibody once approved by FDA for treatment of metastatic breast cancer in combination with chemotherapy.
Study Locations (1 sites)
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≥18 years and ≤80 years; 2. Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging; 3. Presence of at least one measurable lesion according to RECIST 1.1; 4. Expected survival ≥3 months; 5. Eastern Cooperative Oncology Group performance status (ECOG PS) : 0-2; 6. Patients who have not previously received antitumor systemic therapy for the stage of relapse or metastasis; 7. For subjects who have previously undergone adjuvant/neoadjuvant therapy, the time from the end of the last chemotherapy (including taxanes) to randomization should be ≥12 months; The time from the end of radical radiotherapy to randomization should be ≥6 months. 8. Major organs show good function, and the relevant examination indexes within 7 days prior to randomization meet the following requirements: * Absolute neutrophil count ≥ 1.5 x 10\^9 / L; * Platelet count ≥ 100 x 10\^9 / L; * Hemoglobin ≥ 90 g/L; * Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 × upper limit of normal (ULN); ALT and AST≤5 × ULN if liver metastasis is present; * Creatinine clearance rate(Ccr) ≥60 mL/min according to the Cockcroft-Gault formula; * Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN, and international normalized ratio (INR)≤1.5 × ULN. 9. Subjects voluntarily agree to participate in the study and sign informed consent, with good compliance and being accessible for treatment and follow-up. Exclusion Criteria: 1. Patients who are pregnant or breast-feeding; 2. Patients with multiple factors affecting oral medication (such as swallow inability, chronic diarrhea and intestinal obstruction); 3. Known hypersensitivity reaction to any of the components of the treatment; 4. Peripheral neuropathy ≥ grade 2, whatever the cause; 5. Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate \<50 at rest) or heart rate-corrected QT interval via Fridericia (QTcF) ≥470 msec. 6. Patients with urinary protein ≥++ indicated by routine urine examination, and the 24-hour urine protein level was confirmed to be \> 1.0g; 7. Patients with imaging showing that the tumor has invaded important blood vessels or the investigator judges that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study; 8. Patients who have experienced arteriovenous or venous thrombosis events within 6 months prior to randomization, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism; 9. Any bleeding or bleeding event ≥grade 3 within 4 weeks prior to the first dose of therapy; Or the presence of unhealed wounds, fractures, gastrointestinal diseases such as gastric and duodenal active ulcers, ulcerative colitis, or active bleeding of unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the investigator; 10. Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites) which requires frequent drainage procedures; 11. Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix; 12. Participants in clinical trials of other antitumor drugs within 4 weeks prior to randomization; 13. Other circumstances in which participation in the study would be inappropriate as determined by the investigator.
Conditions Fibrosis, Breast Cancer, Head and Neck C...
Phase NA
Enrollment 110
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

FIBROTHERME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial. The aim of this study is to evaluate the medical benefit in terms of quality of life on the dermatological sequelae of fibrosis 6 months after a dermatologically oriented spa therapy in patients with severe late reactions affecting the skin and/or soft tissues at least 6 months after radiotherapy for breast cancer or UADT (Upper Aerodigestive Tract) cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Other: Thermal cure with a primary dermatological indication — The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)

Primary Outcomes

  • Evaluation of the medical benefit in terms of quality of life on the dermatological sequelae of fibrosis after a dermatologically oriented spa treatment. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-29
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Association Francaise pour la Recherche Thermale
Collaborators: Floralis
Principal Investigators:
  • Guillaume Vogin (PRINCIPAL_INVESTIGATOR) - Centre François Baclesse
Contact Information
Study Contact:
Nans FUSTIER
0476765040
nans.fustier@univ-grenoble-alpes.fr
Claire Eychenne
0476766413
claire.eychenne@univ-grenoble-alpes.fr
Christophe Debelleix
christophedebelleix@yahoo.fr
Clinique Tivoli-Ducos
Interventions
  • Other: Thermal cure with a primary dermatological indication — The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
Study Locations (13 sites)
Clinique Tivoli-Ducos, Bordeaux, 33000 France
Centre Hospitalier Intercommunal Créteil, Créteil, 94000 France
Institut de Cancérologie de Bourgogne, Dijon, 21000 France
Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, 38000 France
Groupe Hospitalier Mutualiste de Grenoble, Grenoble, 38000 France
Institut Rafael, Levallois-Perret, France
Institut Paoli-Calmettes, Marseille, 13009 France
Centre Azuréen de Cancérologie, Mougins, France
Centre Eugène Marquis, Rennes, 35000 France
Centre Hospitalier Roanne, Roanne, France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * In situ or invasive breast cancer or cancer of the upper aerodigestive tract * DLQI ≥ 6 (at least moderate effect on patient's life) * General status WHO 0-1 * Radiotherapy completed at least 6 months ago (with no maximum post radiotherapy delay) * Unilateral breast radiotherapy for breast cancer patients * Skin or soft tissue toxicity (- modules: Skin atrophy, fibrosis of deep connective tissues, fibrosis of superficial soft tissues) CTCAE v4.0 grade ≥ 2 * No inflammatory or infectious flare at inclusion * Female of childbearing potential: negative urine pregnancy test at inclusion * Patient informed and signed consent * Affiliation to a social security systeme or equivalent Exclusion Criteria: * Progressive phase of cancer * Metastatic disease * Patient undergoing specific treatment for breast cancer (except adjuvant hormone therapy and/or adjuvant herceptin) * Bilateral breast/parietal radiotherapy * Breast prosthesis wearer for breast cancer patients * Patient with a tracheostomy for patients with head and neck cancer * Obvious skin ulceration in the site of interest * Contraindication to spa treatment (acute inflammatory disease, active infections, heart failure with NYHA stage \> 1, chronic respiratory failure, labile hypertension, bullous disease) * Chronic progressive dermatological disease * Women who are pregnant or likely to become pregnant within 6 months or who are breastfeeding * Persons deprived of liberty or under guardianship
Conditions Breast Carcinoma
Phase Not Applicable
Enrollment 162
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Other: Laboratory Biomarker Analysis — Correlative studies

Primary Outcomes

  • Identification of rare coding variants of large effect that predict the risk of CHF (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2014-03-25
Completion: 2100-01-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Bryan P Schneider (PRINCIPAL_INVESTIGATOR) - Eastern Cooperative Oncology Group
Contact Information
Study Contact:
Bryan P. Schneider
317-274-6473
bpschnei@iupui.edu
Eastern Cooperative Oncology Group
Bryan P. Schneider
Eastern Cooperative Oncology Group
Interventions
  • Other: Laboratory Biomarker Analysis — Correlative studies
Study Locations (1 sites)
Eastern Cooperative Oncology Group, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: * European American patients with DNA available * European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab * African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls
Conditions Breast, Metastatic, Triple Negative, Can...
Phase PHASE1, PHASE2
Enrollment 65
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locally advanced TNBC are at high risk of developing lethal metastatic disease within 2 years of diagnosis, especially for those without a pathologic complete response (pCR) after neoadjuvant chemotherapy. The high risk occurs despite surgical excision of the primary tumor and axillary lymph nodes to eliminate residual disease.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — Capecitabine 1000 mg BID
  • Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine — Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
  • Combination Product: Sarilumab 150mg plus Capecitabine — Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.

Primary Outcomes

  • Phase I: Maximum Tolerated Dose (MTD) (first treatment up to 9 weeks)
  • Phase I: Dose-limiting toxicity (DLT) (first treatment up to 9 weeks)
  • Phase II:To determine the percent of patients with positive CTCs and DTCs (if available) becoming negative CTCs and DTCs (if available) after treatment (baseline up to 14 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2020-09-26
Completion: 2027-05-03
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 65 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Anastasia Martynova, MD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Kimberly Arieli, RN
323-865-3935
Kimberly.Arieli@med.usc.edu
Kimberly Arieli, RN
323-865-3935
Kimberly.Arieli@med.usc.edu
Los Angeles General Medical Center
Anastasia Martynova, MD
Los Angeles General Medical Center
Interventions
  • Drug: Capecitabine — Capecitabine 1000 mg BID
  • Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine — Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
  • Combination Product: Sarilumab 150mg plus Capecitabine — Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
Study Locations (3 sites)
Los Angeles General Medical Center, Los Angeles, California 90033 United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
UF Health, Gainesville, Florida 32610 United States
Eligibility Criteria
Inclusion Criteria: * A. Written informed consent obtained from the subject and the ability for the subject to comply with all the study-related procedures. * B. Both males and females ≥ eighteen years of age * C. A clinical diagnosis of metastatic triple negative or hormone resistant, Her2/neu-negative breast cancer that has been confirmed histologically at one point during the course of the disease. TNBC is defined as ER/PR IHC positivity rate of \<10% and Her2Neu-negative (Phase I only) * D. A life expectancy of at least 6 months. (Phase I only) * E. Any previous cytotoxic chemotherapy must have been a minimum of 3 weeks prior to study drug administration. There is no limit on the number of prior therapies. For ER/PR-positive tumors, endocrine therapy must have been included in at least one of those prior regimens. Prior capecitabine is allowed only if not given in the treatment regimen immediately prior to the enrollment in this study. (Phase I only) * F. A diagnosis of TNBC confirmed histologically and defined as ER/PR IHC positivity rate of \<10% and Her2/neu-negative. (Phase II and Parallel Baseline Arm only) * G. A pathologic confirmation of stage I, or II, or III breast cancer with less than a complete pCR, defined as the absence of residual invasive cancer in resected breast specimen and sampled lymph nodes with residual noninvasive cancer or in situ disease allowed. (Phase II and Parallel Baseline Arm only) * H. Must not have received prior systemic treatment for breast cancer except for those included in the neoadjuvant regimen and the neoadjuvant regimen must not have included capecitabine nor sarilumab. (Phase II and Parallel Baseline Arm only) * I. An ECOG Performance Status ≤2. * J. Adequate organ function defined as: 1. Absolute neutrophil count (ANC) \> 1500/mcl (use of G-CSF is allowed) 2. Platelets ≥ 100,000/mcl 3. Hemoglobin ≥ 9 (pRBC +/- ESA are allowed) 4. ALT ≤ 5 x ULN 5. AST ≤ 5 x ULN 6. Bilirubin ≤ 3 x ULN 7. GFR ≥ 30 ml/min * K. Women of childbearing potential (WOCBP) must be using a highly effective method of contraception to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. * L. Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug. Exclusion Criteria: * A. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 24 weeks after the last dose of study drug. * B. Females who are pregnant or breastfeeding. * C. History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. * D. Hepatitis B infection except for prior vaccination. (Phase I and Phase II only). * E. Known history of tuberculosis injection. (Phase I and Phase II only). * F. A history of diverticulitis. (Phase I and Phase II only). * G. Use of live vaccines within 30 days prior to study treatment due to the risk of infection. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella (MMR), varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed. (Phase I and Phase II only) * H. History of other malignancy that in the primary oncologist's estimation has at the time of study participation a higher risk of recurrence or death than the study-related cancer. * I. Prisoners or subjects who are involuntarily incarcerated. * J. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * K. Subjects demonstrating an inability to comply with the study and/or follow-up procedures.
Conditions Breast Cancer
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: TN — Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
  • Drug: TN-1 — Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC

Primary Outcomes

  • pathological complete response (pCR) (Baseline to surgery)
  • ctDNA clearance rate (Before Neoadjuvant chemotherapy to surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-30
Completion: 2040-06-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nagoya City University
Collaborators: Japan Clinical Oncology Group
Contact Information
Study Contact:
Kazuki Nozawa, MD
052-853-8628
k.nozawa@med.nagoya-cu.ac.jp
Nagoya City University
Kazuki Nozawa, MD
Nagoya City University
Interventions
  • Drug: TN — Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
  • Drug: TN-1 — Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Study Locations (1 sites)
Nagoya City University, Nagoya, Aichi-ken 467-8601 Japan
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed invasive breast carcinoma 2. Stage II or III 3. ECOG performance status of 0 or 1 4. Age 18-80 Exclusion Criteria: 1. Continuous systemic administration (oral or intravenous) of steroid drugs or other immunosuppressants. 2. History or complication of interstitial lung disease or pulmonary fibrosis diagnosed by imaging or clinical findings. 3. Infection requiring systemic treatment. 4. Active double cancer (however, the following are not excluded: (1) Completely resected cancers: basal cell carcinoma, squamous cell carcinoma at clinical stage I, carcinoma in situ, mucosal carcinoma, superficial bladder carcinoma, (2) Gastrointestinal cancer that has been curatively resected by ESD or EMR, (3) Other cancers that have not recurred for more than 5 years).
Conditions Breast Cancer
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing the effects of a ketogenic diet on patients with early stage breast cancer. Participants will keep to a ketogenic diet for 3 weeks prior to surgery.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: Ketogenic diet — The ketogenic diet will be comprised of a low carbohydrate, high fat diet.

Primary Outcomes

  • Change in tumor immune microenvironment (Baseline to 3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-02
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Saba Shaikh, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Joseph Terrones
210-450-5098
terronesj@uthscsa.edu
Kayla Chamberlin, RN, BSN
210-450-5964
chamberlink@uthscsa.edu
Joseph Terrones
210-450-5098
terronesj@uthscsa.edu
Mays Cancer Center, UT Health San Antonio
Interventions
  • Other: Ketogenic diet — The ketogenic diet will be comprised of a low carbohydrate, high fat diet.
Study Locations (1 sites)
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: * Be willing and able to provide consent for the study * Age ≥ 18 on the day consent is obtained * Eastern Cooperative Oncology Group (ECOG) score ≤ 2 * Patients must be postmenopausal the time of study entry * Stage I or II breast cancer using Tumor, Nodes and Metastasis (TNM) stage groups per American Joint Committee on Cancer (AJCC) 8th edition * Plan for upfront breast surgery with mastectomy or partial mastectomy and does not require pre-operative systemic therapy per standard of care * Must have tissue available from initial breast biopsy performed per standard of care * have the ability in the opinion of the investigator to adhere to a ketogenic diet and comply with study requirements such as ability to participate in telemedicine, utilize apps on a smart device, measure glucose/ketones at home, accurately log food intake and exercise, prepare food that is in line with ketogenic diet Exclusion Criteria: * Clinical indication for neoadjuvant therapy * Partial mastectomy or mastectomy planned for less than 3 weeks from study entry * Inability to comply with ketogenic diet * Consistent use of ketogenic diet within past 3 months * Participation in another diet program during study period * Nonepithelial breast malignancy such as sarcoma or lymphoma * Body Mass Index \< 18.5 * Comorbidities and/or active or ongoing illness that in the opinion of the investigator will limit patient's ability to safely participate in study * Type I diabetes * Use of insulin or other oral hypoglycemic drugs for diabetes * Has had any of the following within the past 6 months * Myocardial infarction or unstable angina * Ventricular arrythmia * Acute decompensated heart failure * Cerebrovascular accident * Hypertensive emergency * Uncontrolled hypertension despite antihypertensive use * End-stage renal, liver, or cardiac disease * genetic disorders that affect lipid metabolism (example: pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects, among others) * G6PD (glucose-6-phosphate dehydrogenase) deficiency * Malabsorption syndromes (such as but not limited to inflammatory bowel disease, history of gastric sleeve, prior bowel resection) * History of recurrent kidney stones or predisposition to kidney stones * Triglycerides ≥ 500 * Has known psychiatric or substance use disorders that would interfere with participation in the study
Conditions Real Time Pressure Controller, Breast Ca...
Phase NA
Enrollment 118
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance. The application of cold compresses or gloves or socks with certain wrapping force is not suitable for the Chinese population, and the acceptance degree of Chinese patients is poor, and the pressure gloves lack individual specificity, and the precise control of pressure for real-time regulation cannot be realized, and the clinical effect is relatively poor. The purpose of this utility model device is to overcome the deficiencies of the existing technology, to provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, and the pressure decreases in a sequential manner from the distal end (toes/fingers) to the proximal end (wrist, limb). After applying for the patent, it will be transformed into the market, which has a vast space of medical benefits and market benefits. Paclitaxel is the cornerstone drug in breast cancer chemotherapy, and the neuropathy it causes is often a key factor leading to drug reduction or discontinuation, so opening up the prevention of peripheral neuropathy caused by paclitaxel is of great clinical use.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Real Time Pressure Controller — The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance.

Primary Outcomes

  • CIPN-related symptoms, as assessed by changes in tactile sensitivity at pretreatment baseline CIPN incidence.The Patient Neurotoxicity Questionnaire (PNQ) was used to assess and grade the incidence and severity of CIPN. (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-01
Completion: 2026-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Contact Information
Study Contact:
Yongsheng Jia
(022)65150123-8212
jiayongsheng@tjmuch.com
Yongsheng Jia
(022)65150123-8212
jiayongsheng@tjmuch.com
Tianjin Medical University Cancer Institute and Hospital
Interventions
  • Device: Real Time Pressure Controller — The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance.
Study Locations (1 sites)
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily signed written informed consent; 2. Age ≥18 years and ≤75 years at enrollment, male or female patients; 3. Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1; 4. Suitable for albumin-paclitaxel antitumor therapy; 5. Cardiopulmonary, hepatic, renal, and coagulation functions are basically normal. Exclusion Criteria: 1. Patients with prior chemotherapy; 2. Patients with a prior diagnosis of peripheral neuropathy; 3. Patients with a prior diagnosis of associated comorbidities (e.g., diabetes mellitus).
Conditions Metastatic Breast Cancer, Breast Cancer
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase I trial of the safety of image-guided pulsed electric field (PEF) ablation for the locoregional treatment of superficial soft tissue lesions in adults with metastatic breast cancer using the AliyaTM Pulsed Electric Field System.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Pulsed Electric Field (PEF) System — Pulsed electric field (PEF) delivers short, high frequency electrical pulses that are intended to shrink or destroy tumors
  • Behavioral: Questionnaires — Participants will complete health related, quality of life questionnaires
  • Procedure: Tumor Ablation — Undergo ablation via PEF

Primary Outcomes

  • Proportion of participants with treatment-emergent adverse events (Up to 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-29
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: Galvanize Therapeutics, Inc., Society of Interventional Radiology Foundation
Principal Investigators:
  • Ryan Kohlbrenner, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Maya Aslam
877-827-3222
maya.aslam@ucsf.edu
Maya Aslam
877-827-3222
Maya.Aslam@ucsf.edu
University of California San Francisco
cancertrials@ucsf.edu
University of California San Francisco
Interventions
  • Device: Pulsed Electric Field (PEF) System — Pulsed electric field (PEF) delivers short, high frequency electrical pulses that are intended to shrink or destroy tumors
  • Behavioral: Questionnaires — Participants will complete health related, quality of life questionnaires
  • Procedure: Tumor Ablation — Undergo ablation via PEF
Study Locations (1 sites)
University of California San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants must have histologically or cytologically confirmed metastatic breast cancer. 2. Confirmed documented soft tissue involvement via imaging or biopsy, with at least one measurable lesion with a cutaneous and/or subcutaneous component that is at least 1 cm in size but no greater than 5 cm in size and that can be safely accessed under image guidance. Up to 3 lesions that meet these criteria may be treated with PEF ablation therapy. 3. There are no limits on the amount of prior or concurrent anti-cancer therapies, but patients must be medically able (in the opinion of referring provider and treating investigator) to withhold their systemic therapy for breast cancer one week before the PEF ablation and for 2 weeks after the procedure. 4. Age ≥18 years 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 6. Adequate Bone Marrow Function: 1. Absolute neutrophil count ≥1,500/microliter (mcL). 2. Platelets ≥100,000/mcL. 7. Not on or able to withhold anticoagulation or antiplatelet therapy per Society of Interventional Radiology periprocedural guideline. 8. Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months (as documented in the medical record) are eligible for this trial. 9. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy (as documented in the medical record), if indicated. 10. Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load (as documented in the medical record). 11. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. 12. The effects of pulsed electric field on the developing human fetus are unknown. For this reason individuals of reproductive potential must agree to use adequate contraception: (e.g., hormonal or barrier method of birth control; abstinence, etc.) for the duration of study participation and for 4 weeks after last administration of study treatment. Should a study participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately. Exclusion Criteria: 1. Has not recovered from adverse events due to prior/concurrent systemic anti-cancer therapy to ≤ Grade 2 (CTCAE v5.0) or baseline (other than alopecia). 2. Individuals with pacemakers or other electronic implant devices. 3. Individuals who are unable or unwilling, or with medical contraindication, to undergo moderate sedation and local anesthesia. 4. Pregnant individuals are excluded from this study because there is unknown risk of PEF on fetus. 5. Breastfeeding/chestfeeding individuals are excluded from this study because there is unknown risk on nursing infants; breastfeeding/chestfeeding should be discontinued prior to initiating study treatment. 6. Individuals with any condition or social circumstance that, in the opinion of the treating investigator, would impair the participant's ability to comply with study procedures.